Asset profile
Alectinib · Alecensa
Small molecule
Evidence outlook
Approved: Non-Small Cell Lung Cancer (label: ALK-positive)
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
65 competitors in this universe: 5 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Alectinib (Alecensa): this drug | Approved | Small molecule | ALK | ||
| Brigatinib | Approved | Small molecule | ALK | ||
| Ceritinib | Approved | Small molecule | ALK | ||
| Ensartinib | Approved | Small molecule | ALK | ||
| Neladalkib NVL-655 | Phase 3 | Small molecule | ALK | ||
| AQUA07 | Phase 1 | Small molecule | ALK | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Binimetinib | Approved | Small molecule | MEK1/2 | ||
| Capmatinib | Approved | Small molecule | MET |
…and 50 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(21 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (5)
November 2026 (3)
What to watch
What to watch
What to watch
2027 (3)
June 2027 (1)
What to watch
September 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (2)
2029 (6)
January 2029 (3)
What to watch
What to watch
What to watch
April 2029 (1)
What to watch
October 2029 (2)
What to watch
What to watch
2030 (1)
June 2030 (1)
What to watch
2031 (1)
August 2031 (1)
What to watch
2032 (2)
2038 (1)
December 2038 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.